The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
Regeneron has announced that the European Commission ... Gynaecological Oncological Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old – 78% with ...
EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...
Mphasis, (BSE: 526299) (NSE: MPHASIS), an Information Technology (IT) solutions provider specializing in cloud and ...
Uveitis Treatment Market Analysis of Uveitis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, ...
Bybit, the world's second-largest cryptocurrency exchange by trading volume, released the latest weekly crypto derivatives ...
The biotech retained the option to commercialize the asset in Japan, with Novartis holding ... according to the release. Sanofi and Regeneron have worked for years to challenge Xolair’s CSU ...
Zacks Investment Research on MSN7d
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...
Hosted on MSN10d
Stocks Fall on Growth Fears and Tech Stock PlungeJapan’s Nikkei Stock 225 recovered from a 5-1/2 month low ... ServiceNow (NOW) closed down more than -7% after agreeing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback